NEUROPATH THERAPEUTICS LIMITED

Neuropath Therapeutics Limited is a Dublin‑based biotechnology company operating at the late pre‑clinical stage, dedicated to developing first‑in‑class therapeutics for neurodegenerative diseases. Building on pioneering research from Trinity College Dublin, the firm is creating a novel class of drugs centred on thyrotropin‑releasing hormone (TRH), a naturally occurring neuropeptide recognised for its ability to counteract several pathogenic mechanisms that drive conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS/MND) and traumatic brain injury.

The company’s lead TRH‑based compound has successfully completed an extensive pre‑clinical programme with top‑tier contract research organisations, including IND/CTA‑enabling work. It has been granted orphan‑drug designation for ALS by both the FDA and EMA and is now poised to enter first‑in‑human Phase 1 trials. Pre‑clinical proof‑of‑concept data show the molecule reduces glutamate‑induced excitotoxicity, mitigates oxidative stress, protects neurons from death and improves both cognitive and motor outcomes.

Neuropath’s multifactorial neurotherapeutic strategy aims to deliver disease‑modifying treatments that alleviate cognitive and motor impairments, ultimately slowing disease progression for patients whose brain health is compromised.